Orally bioavailable factor Xa inhibitors containing alpha-substituted gem-dimethyl P4 moieties
摘要:
In an effort to identify a potential back-up to apixaban (Eliquie (R)), we explored a series of diversified P4 moieties. Several analogs with substituted gem-dimethyl moieties replacing the terminal lactam of apixaban were identified which demonstrated potent FXa binding affinity (FXa K-i), good human plasma anticoagulant activity (PT EC2x), cell permeability, and oral bioavailability. (C) 2014 Elsevier Ltd. All rights reserved.
[EN] 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS<br/>[FR] DERIVES CYCLOALKYLES 1,1-DISUBSTITUES UTILISES EN TANT QU'INHIBITEURS DU FACTEUR XA
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2003099276A1
公开(公告)日:2003-12-04
The present application describes 1,1-disubstituted cycloalkyl compounds and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.
1,1-Disubstituted cycloalkyl derivatives as factor Xa inhibitors
申请人:——
公开号:US20040254158A1
公开(公告)日:2004-12-16
The present application describes 1,1-disubstituted cycloalkyl compounds and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.
1, 1-disubstituted cycloalkyl derivatives as factor Xa inhibitors
申请人:Bristol-Myers Squibb Company
公开号:US07312214B2
公开(公告)日:2007-12-25
The present application describes 1,1-disubstituted cycloalkyl compounds and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.